Who Enrolled in a Randomized Controlled Trial of Quitline Support? Comparison of Participants Versus Nonparticipants

被引:4
|
作者
Tzelepis, Flora [1 ,2 ]
Paul, Christine L. [1 ,2 ]
Walsh, Raoul A. [2 ,3 ]
Knight, Jenny [1 ,2 ,4 ,5 ]
Wiggers, John [1 ,2 ,4 ,5 ]
机构
[1] Univ Newcastle, Prior Res Ctr Hlth Behav, Callaghan, NSW 2308, Australia
[2] Hunter Med Res Inst, Callaghan, NSW 2308, Australia
[3] Univ Newcastle, Ctr Hlth Res & Psychooncol, Canc Council New South Wales, Callaghan, NSW 2308, Australia
[4] Univ Newcastle, Hunter New England Populat Hlth, Hunter New England Local Hlth Dist, Wallsend, NSW, Australia
[5] Hunter Med Res Inst, Wallsend, NSW, Australia
基金
澳大利亚研究理事会;
关键词
SMOKING-CESSATION TREATMENTS; TOBACCO CESSATION; TELEPHONE; RECRUITMENT; PREDICTORS;
D O I
10.1093/ntr/ntt114
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction: Understanding the characteristics of smokers who enroll in a trial of quitline support and those who decline could guide recruitment approaches and service delivery to better engage smokers and increase successful quitting. However, it is unknown whether factors such as smokers' perceived effectiveness of using quitting aids or self-exempting beliefs are associated with quitline uptake. We compared the sociodemographic characteristics, smoking behaviours, perceived effectiveness of using quitting aids, and self-exempting beliefs of participants and nonparticipants who were actively telephoned and offered quitline support as part of a randomized controlled trial. Methods: Overall, 48,014 telephone numbers were randomly selected from the electronic telephone directory and contacted. A total of 3,008 eligible smokers were identified and invited to participate in a trial of quitline support. Consenting trial participants (n = 1,562) and nonparticipants (n = 500) completed a baseline interview. Results: Multivariate analysis showed that the following factors were associated with trial participation: consumption of 21 or more cigarettes per day (odds ratio [OR] = 1.45 [1.07-1.99]), readiness to quit within 30 days (OR = 4.45 [3.20-6.19]) or 6 months (OR = 3.22 [2.46-4.23]), perceiving that calling the quitline was definitely (OR = 2.34 [1.62-3.39]) or partly effective (OR = 2.15 [1.63-2.83]), believing that using self-help materials was partly effective (OR = 1.50 [1.16-1.94]), thinking that nicotine replacement therapy was partly effective (OR = 1.38 [1.04-1.84]), perceiving that using willpower alone was partly (OR = 1.99 [1.48-2.67]) or not effective (OR = 2.60 [1.95-3.46]), and not holding a self-exempting belief (OR = 1.45 [1.11-1.89]). Conclusions: Increasing smokers' utilization of quitlines is likely to require changing their perceptions of the effectiveness of quitting strategies compared with using willpower alone and addressing self-exempting beliefs.
引用
收藏
页码:2107 / 2113
页数:7
相关论文
共 50 条
  • [31] Comparison of an automated smartphone-based smoking cessation intervention versus standard quitline-delivered treatment among underserved smokers: protocol for a randomized controlled trial
    Jennifer I. Vidrine
    Ya-Chen Tina Shih
    Michael S. Businelle
    Steven K. Sutton
    Diana Stewart Hoover
    Cherell Cottrell-Daniels
    Bethany Shorey Fennell
    Kristina E. Bowles
    Damon J. Vidrine
    BMC Public Health, 22
  • [32] "Rescue" of Nonparticipants in Colorectal Cancer Screening: A Randomized Controlled Trial of Three Noninvasive Test Options
    Young, Graeme Paul
    Chen, Gang
    Wilson, Carlene J.
    McGrane, Ellen
    Hughes-Barton, Donna Lee-Ann
    Flight, Ingrid Helen K.
    Symonds, Erin Leigh
    CANCER PREVENTION RESEARCH, 2021, 14 (08) : 803 - 810
  • [33] Comparison of an automated smartphone-based smoking cessation intervention versus standard quitline-delivered treatment among underserved smokers: protocol for a randomized controlled trial
    Vidrine, Jennifer, I
    Shih, Ya-Chen Tina
    Businelle, Michael S.
    Sutton, Steven K.
    Hoover, Diana Stewart
    Cottrell-Daniels, Cherell
    Fennell, Bethany Shorey
    Bowles, Kristina E.
    Vidrine, Damon J.
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [34] Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial
    Fishbein, Nathan S.
    Vranceanu, Ana-Maria
    Mace, Ryan A.
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (03) : 637 - 646
  • [35] Peer Texting to Promote Quitline Use and Smoking Cessation Among Rural Participants in Vietnam: Randomized Clinical Trial
    Sadasivam, Rajani S.
    Nagawa, Catherine S.
    Wijesundara, Jessica G.
    Flahive, Julie
    Nguyen, Hoa L.
    Larkin, Celine
    Faro, Jamie M.
    Balakrishnan, Kavitha
    Ha, Duc Anh
    Nguyen, Cuong Kieu
    Vuong, Anh
    Phan, Phuong Thu
    Pham, Quyen Phi Li
    Allison, Jeroan J.
    Houston, Thomas Karr
    INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2024, 69
  • [36] Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial
    Nathan S. Fishbein
    Ana-Maria Vranceanu
    Ryan A. Mace
    Journal of Neuro-Oncology, 2022, 159 : 637 - 646
  • [37] Comparison of alprazolam versus captopril in high blood pressure: A randomized controlled trial
    Yilmaz, Serkan
    Pekdemir, Murat
    Tural, Umit
    Uygun, Mecit
    BLOOD PRESSURE, 2011, 20 (04) : 239 - 243
  • [38] Comparison of needlescopic appendectomy versus conventional laparoscopic appendectomy - A randomized controlled trial
    Lau, DHW
    Yau, KKK
    Chung, CC
    Leung, FCS
    Tai, YP
    Li, MKW
    SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, 2005, 15 (02): : 75 - 79
  • [39] Intrapatient Comparison of Coblation versus Electrocautery Tonsillectomy in Children: A Randomized, Controlled Trial
    Choi, Kyu Young
    Ahn, Jae-Cheul
    Rhee, Chae-Seo
    Han, Doo Hee
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
  • [40] Comparison of Intravenous Morphine Versus Paracetamol in Sciatica: A Randomized Placebo Controlled Trial
    Serinken, Mustafa
    Eken, Cenker
    Gungor, Faruk
    Emet, Mucahit
    Al, Behcet
    ACADEMIC EMERGENCY MEDICINE, 2016, 23 (06) : 674 - 678